Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)
Clinical trial NCT02387372 · COMPLETED
Trial details
- NCT number
- NCT02387372
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-02-05
- Primary completion
- 2017-06-15
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.